Acute myeloblastic leukemia achieving complete remission with Amifostine alone

Ozturk A., Orhan B., Turken O., Etiz D., Yaylaci M., Uskent N.

LEUKEMIA & LYMPHOMA, vol.43, no.2, pp.451-453, 2002 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 2
  • Publication Date: 2002
  • Doi Number: 10.1080/10428190290006341
  • Journal Name: LEUKEMIA & LYMPHOMA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.451-453
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Amifostine, a phosphorylated thiol-amine, is known as a cytoprotective agent especially for cisplatin containing chemotherapies. Apart from the cytoprotective role, Amifostine could also be used in the treatment of hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML), as a treatment option or for potentiating the effects of cytotoxic agents.